サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1229676

アスペルガー症候群の世界市場：2030年までの予測

Asperger Syndrome Market Research Report Forecast Till 2030
出版日: | 発行: Market Research Future | ページ情報: 英文 100 Pages | 納期: お問合せ

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
アスペルガー症候群の世界市場：2030年までの予測
出版日: 2023年03月03日
発行: Market Research Future
ページ情報: 英文 100 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のアスペルガー症候群の市場規模は、2030年までの調査期間中に3.70%のCAGRで成長すると予測されています。精神薬理学の進歩により、明確な患者をターゲットにした薬物療法が行われるようになり、その結果、より適切な薬物療法が行われるようになったことが、市場の成長を促進しています。

当レポートでは、世界のアスペルガー症候群市場について調査分析し、市場力学、市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートプロローグ

第2章 市場イントロダクション

  • 定義
  • 調査範囲
    • 調査目的
    • 仮定
    • 制限事項

第3章 調査手法

  • イントロダクション
  • 1次調査
  • 2次調査
  • 市場規模の推定

第4章 市場力学

  • 促進要因
  • 抑制要因
  • 機会
  • 課題
  • マクロ経済指標
  • 技術動向と評価

第5章 市場要因分析

  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争の激しさ
  • バリューチェーン分析
  • 投資実現可能性分析
  • 価格分析

第6章 世界のアスペルガー症候群市場：診断別

  • イントロダクション
  • DSM-IV
  • 鑑別診断
  • 小児アスペルガー症候群検査
  • ギリアムアスペルガー障害スケール（GADS）
  • クリュッグアスペルガー症候群指数（KADI）
  • その他

第7章 世界のアスペルガー症候群市場：治療別

  • イントロダクション
  • 親の教育とトレーニング
  • ソーシャルスキルトレーニング
  • 言語療法
  • 応用行動分析（ABA）
  • 投薬

第8章 世界のアスペルガー症候群市場：エンドユーザー別

  • イントロダクション
  • 病院
  • クリニック
  • 診断センター
  • ドラッグストア
  • 薬局
  • その他

第9章 世界のアスペルガー症候群市場：地域別

  • イントロダクション
  • 南北アメリカ
    • 北米
    • 南米
  • 欧州
    • 西欧
    • 東欧
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 大韓民国
    • その他のアジア太平洋地域
  • 中東とアフリカ
    • アラブ首長国連邦
    • サウジアラビア
    • オマーン
    • クウェート
    • カタール
    • その他の中東およびアフリカ

第10章 企業情勢

  • イントロダクション
  • 市場シェア分析
  • 主な開発と戦略
    • 主な開発

第11章 企業プロファイル

  • ELI LILLY AND COMPANY'S
  • SHIRE
  • JAZZ PHARMACEUTICALS
  • PFIZER
  • GLAXOSMITHKLINE
  • FOREST LABORATORIES, INC.
  • JOHNSON & JOHNSON SERVICES, INC.
  • その他

第12章 MRFRの結論

  • 主な調査結果
    • CEOの視点から
    • アンメットニーズ
  • 注目すべき主要企業
  • アスペルガー症候群産業の予測

第13章 付録

図表

LIST OF TABLES

  • TABLE 1 ASPERGER SYNDROME INDUSTRY SYNOPSIS, 2022-2030
  • TABLE 2 ASPERGER SYNDROME MARKET ESTIMATES & FORECAST, 2022-2030, (USD MILLION)
  • TABLE 3 ASPERGER SYNDROME MARKET, BY REGION, 2022-2030, (USD MILLION)
  • TABLE 4 ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 5 ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 6 ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 7 NORTH AMERICA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 8 NORTH AMERICA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 9 NORTH AMERICA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 10 U.S. ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 11 U.S. ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 12 U.S. ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 13 CANADA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 14 CANADA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 15 CANADA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 16 SOUTH AMERICA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 17 SOUTH AMERICA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 18 SOUTH AMERICA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 19 EUROPE ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 20 EUROPE ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 21 EUROPE ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 22 WESTERN EUROPE ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 23 WESTERN EUROPE ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 24 WESTERN EUROPE ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 25 EASTERN EUROPE ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 26 EASTERN EUROPE ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 27 EASTERN EUROPE ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 28 ASIA PACIFIC ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 29 ASIA PACIFIC ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 30 ASIA PACIFIC ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)
  • TABLE 31 THE MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET, BY DIAGNOSIS, 2022-2030, (USD MILLION)
  • TABLE 32 THE MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET, BY TREATMENT, 2022-2030, (USD MILLION)
  • TABLE 33 THE MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET, BY END-USER, 2022-2030, (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 RESEARCH PROCESS
  • FIGURE 2 SEGMENTATION FOR THE ASPERGER SYNDROME MARKET
  • FIGURE 3 SEGMENTATION MARKET DYNAMICS FOR THE ASPERGER SYNDROME MARKET
  • FIGURE 4 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY DIAGNOSIS, 2022
  • FIGURE 5 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY TREATMENT, 2022
  • FIGURE 6 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY END-USER, 2022
  • FIGURE 7 GLOBAL ASPERGER SYNDROME MARKET SHARE, BY REGION, 2022
  • FIGURE 8 NORTH AMERICA ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 9 EUROPE ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 10 ASIA PACIFIC ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 11 MIDDLE EAST & AFRICA ASPERGER SYNDROME MARKET SHARE, BY COUNTRY, 2022
  • FIGURE 12 GLOBAL ASPERGER SYNDROME MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
  • FIGURE 13 ELI LILLY AND COMPANY'S: KEY FINANCIALS
  • FIGURE 14 ELI LILLY AND COMPANY'S: SEGMENTAL REVENUE
  • FIGURE 15 ELI LILLY AND COMPANY'S: GEOGRAPHICAL REVENUE
  • FIGURE 16 SHIRE: KEY FINANCIALS
  • FIGURE 17 SHIRE: SEGMENTAL REVENUE
  • FIGURE 18 SHIRE: GEOGRAPHICAL REVENUE
  • FIGURE 19 JAZZ PHARMACEUTICALS: KEY FINANCIALS
  • FIGURE 20 JAZZ PHARMACEUTICALS: SEGMENTAL REVENUE
  • FIGURE 21 JAZZ PHARMACEUTICALS: GEOGRAPHICAL REVENUE
  • FIGURE 22 PFIZER: KEY FINANCIALS
  • FIGURE 23 PFIZER: SEGMENTAL REVENUE
  • FIGURE 24 PFIZER: GEOGRAPHICAL REVENUE
  • FIGURE 25 GLAXOSMITHKLINE: KEY FINANCIALS
  • FIGURE 26 GLAXOSMITHKLINE: SEGMENTAL REVENUE
  • FIGURE 27 GLAXOSMITHKLINE GEOGRAPHICAL REVENUE
  • FIGURE 28 FOREST LABORATORIES, INC.: KEY FINANCIALS
  • FIGURE 29 FOREST LABORATORIES, INC.: SEGMENTAL REVENUE
  • FIGURE 30 FOREST LABORATORIES, INC.: GEOGRAPHICAL REVENUE
  • FIGURE 31 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS
  • FIGURE 32 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE
  • FIGURE 33 JOHNSON & JOHNSON SERVICES, INC.: GEOGRAPHICAL REVENUE
目次
Product Code: MRFR/Pharma/4383-HCR

Market Overview

The Asperger Syndrome market should enlist a CAGR of 3.70% during the forecast time period. Asperger's syndrome is furthermore called Intellectually lopsided Reach Issue which generally begins in youthfulness and continues to stay till death. There are several vital differentiations not entirely set in stone to have a chemical imbalance and those with Asperger's syndrome. A couple of clinical specialists have acknowledged that Asperger's syndrome is a milder type of chemical imbalance. Overall, the secondary effects showed up in Asperger's syndrome are milder; in any case, the children not set in stone to have a chemical imbalance range tangle.

The rising regularity of the chemical imbalance and the extensive variety of the condition are the fundamental clarifications behind the overall advancement of the Asperger syndrome industry. Lately, World Prosperity Affiliation has communicated that there were around 1 of each not set in stone to have a mental imbalance. Progressing assessments show that there are a couple of explanations behind the syndrome, for instance, unforeseen work, a youth brought into the world not long after its kinfolk, family heritage, more prepared gatekeepers, any mental issue, epilepsy, or malignant growth in the psyche. A rising number of purposes behind the condition and normal components have expanded the overall Asperger syndrome marked improvement of late.

The degrees of progress in Psychopharmacology concerning arranging their medications to target unequivocal patients and having less delayed consequences yet more suitable have expanded the overall advancement of the Asperger Syndrome industry recently. While there are still many cases where the necessary medication is not supplied, the increased frequency of chemical imbalance range mix and Asperger syndrome is having a significant impact on the recent growth of the Asperger syndrome market.

Market Segmentation

Asperger Syndrome, Pervasive Developmental Disorder, Autistic Disorder, and Disintegrative Disorder are the several types of disorders that make up the market.

The market is divided into four categories based on deployment: Applied Behavior Analysis (ABA), Speech and Language Therapy, and Occupation Therapy.

Drug Treatments, Antipsychotic Medications, SSRIs, Stimulants, and Sleep Medicine are all included in the Treatment part.

Regional Analysis

America is likely to lead the Asperger Syndrome industry. Over 3.5 million Americans are living with the condition as per a new report. In no less than 10 years, a few locales in America exhibits more than a 119.4% increment concerning the number of cases. The costs brought about in treating the condition have expanded by over USD 236-262 billion lately. Such factors have expanded the general development of the Asperger Syndrome industry.

The administrative drives and presence of driving market players in Europe are the essential purposes behind the development of the Asperger Syndrome industry in Europe. Ease in the repayment approaches and propelling foundation of the medical services places are reinforcing the development of the Asperger Syndrome industry.

Major Players

Asperger Syndrome Market Competitors are Eli Lilly and Company, Shire, Jazz Pharmaceuticals, Pfizer, GlaxoSmithKline, Forest Laboratories, Johnson & Johnson, Bristol-Myers Squibb, Otsuka pharmaceutical, and AstraZeneca.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

TABLE OF CONTENTS:

CHAPTER 1. REPORT PROLOGUE

CHAPTER 2. MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
    • 2.2.1 RESEARCH OBJECTIVE
    • 2.2.2 ASSUMPTIONS
    • 2.2.3 LIMITATIONS

CHAPTER 3. RESEARCH METHODOLOGY

  • 3.1 INTRODUCTION
  • 3.2 PRIMARY RESEARCH
  • 3.3 SECONDARY RESEARCH
  • 3.4 MARKET SIZE ESTIMATION

CHAPTER 4. MARKET DYNAMICS

  • 4.1 DRIVERS
  • 4.2 RESTRAINTS
  • 4.3 OPPORTUNITIES
  • 4.4 CHALLENGES
  • 4.5 MACROECONOMIC INDICATORS
  • 4.6 TECHNOLOGY TRENDS & ASSESSMENT

CHAPTER 5. MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 VALUE CHAIN ANALYSIS
  • 5.3 INVESTMENT FEASIBILITY ANALYSIS
  • 5.4 PRICING ANALYSIS

CHAPTER 6. GLOBAL ASPERGER SYNDROME MARKET, BY DIAGNOSIS

  • 6.1 INTRODUCTION
  • 6.2 DSM-IV
    • 6.2.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.3 DIFFERENTIAL DIAGNOSIS
    • 6.3.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.4 CHILDHOOD ASPERGER SYNDROME TEST
    • 6.4.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.5 GILLIAM ASPERGER'S DISORDER SCALE (GADS)
    • 6.5.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.6 KRUG ASPERGER'S DISORDER INDEX (KADI)
    • 6.6.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 6.7 OTHERS
    • 6.7.1 MARKET ESTIMATES & FORECAST, 2022-2030

CHAPTER 7. GLOBAL ASPERGER SYNDROME MARKET, BY TREATMENT

  • 7.1 INTRODUCTION
  • 7.2 PARENT EDUCATION & TRAINING
    • 7.2.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.3 SOCIAL SKILLS TRAINING
    • 7.3.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.4 SPEECH-LANGUAGE THERAPY
    • 7.4.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.5 APPLIED BEHAVIORAL ANALYSIS (ABA)
    • 7.5.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 7.6 MEDICATION
    • 7.6.1 MARKET ESTIMATES & FORECAST, 2022-2030

CHAPTER 8. GLOBAL ASPERGER SYNDROME MARKET, BY END-USER

  • 8.1 INTRODUCTION
  • 8.2 HOSPITALS
    • 8.2.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.3 CLINICS
    • 8.3.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.4 DIAGNOSTIC CENTERS
    • 8.4.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.5 DRUG STORES
    • 8.5.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.6 PHARMACIES
    • 8.6.1 MARKET ESTIMATES & FORECAST, 2022-2030
  • 8.7 OTHERS
    • 8.7.1 MARKET ESTIMATES & FORECAST, 2022-2030

CHAPTER 9. GLOBAL ASPERGER SYNDROME MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 AMERICAS
    • 9.2.1 NORTH AMERICA
      • 9.2.1.1 U.S.
      • 9.2.1.1 CANADA
    • 9.2.2 SOUTH AMERICA
  • 9.3 EUROPE
    • 9.3.1 WESTERN EUROPE
      • 9.3.1.1 GERMANY
      • 9.3.1.2 FRANCE
      • 9.3.1.3 ITALY
      • 9.3.1.4 SPAIN
      • 9.3.1.5 U.K.
      • 9.3.1.6 REST OF WESTERN EUROPE
    • 9.3.2 EASTERN EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 JAPAN
    • 9.4.2 CHINA
    • 9.4.3 INDIA
    • 9.4.4 AUSTRALIA
    • 9.4.5 REPUBLIC OF KOREA
    • 9.4.6 REST OF ASIA PACIFIC
  • 9.5 THE MIDDLE EAST & AFRICA
    • 9.5.1 UNITED ARAB EMIRATES
    • 9.5.2 SAUDI ARABIA
    • 9.5.3 OMAN
    • 9.5.4 KUWAIT
    • 9.5.5 QATAR
    • 9.5.6 REST OF THE MIDDLE EAST & AFRICA

CHAPTER 10 COMPANY LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 MARKET SHARE ANALYSIS
  • 10.3 KEY DEVELOPMENT & STRATEGIES
    • 10.3.1 KEY DEVELOPMENTS

CHAPTER 11 COMPANY PROFILES

  • 11.1 ELI LILLY AND COMPANY'S
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 TYPES OVERVIEW
    • 11.1.3 FINANCIALS
    • 11.1.4 SWOT ANALYSIS
  • 11.2 SHIRE
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 TYPES OVERVIEW
    • 11.2.3 FINANCIAL OVERVIEW
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
  • 11.3 JAZZ PHARMACEUTICALS
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 TYPES OVERVIEW
    • 11.3.3 FINANCIAL OVERVIEW
    • 11.3.4 KEY DEVELOPMENT
    • 11.3.5 SWOT ANALYSIS
  • 11.4 PFIZER
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 TYPES/BUSINESS SEGMENT OVERVIEW
    • 11.4.3 FINANCIAL OVERVIEW
    • 11.4.4 KEY DEVELOPMENT
    • 11.4.5 SWOT ANALYSIS
  • 11.5 GLAXOSMITHKLINE
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 TYPES OVERVIEW
    • 11.5.3 FINANCIAL OVERVIEW
    • 11.5.4 KEY DEVELOPMENTS
  • 11.6 FOREST LABORATORIES, INC.
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 TYPES OVERVIEW
    • 11.6.3 FINANCIAL OVERVIEW
    • 11.6.4 KEY DEVELOPMENTS
  • 11.7 JOHNSON & JOHNSON SERVICES, INC.
    • 11.7.1 OVERVIEW
    • 11.7.2 TYPES OVERVIEW
    • 11.7.3 FINANCIALS
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 SWOT ANALYSIS
  • 11.8 OTHERS

CHAPTER 12 MRFR CONCLUSION

  • 12.1 KEY FINDINGS
    • 12.1.1 FROM CEO'S VIEW POINT
    • 12.1.2 UNMET NEEDS OF THE MARKET
  • 12.2 KEY COMPANIES TO WATCH
  • 12.3 PREDICTION OF ASPERGER SYNDROME INDUSTRY

CHAPTER 13 APPENDIX